XenTech is a French company part of the top 10 preclinical CRO’s active in oncology offering support to early drug development. Our services are governed by a stringent QA system (“GLP-like”).
XenTech’s technology is based on one of the world’s largest and best characterized collection of Patient-Derived primary tumor Xenograft models (PDX). Our panel includes exclusive pediatric models, resistant "Match-R" models. We also offer immuno-oncology dedicated panel.
Our ambition is to foster therapeutic development in Oncology by offering an innovative translational platform, developing clinically relevant tumor models and addressing tomorrow’s needs in preclinical oncology research.
XenTech’s PDX platform is an outstanding tool for cancer biomarker discovery.
Large tumor panels recapitulate the biological heterogeneity of patient populations, a key parameter for the evaluation of molecular targeted agents.
Indeed, tumor xenografts of the same histological subtype often demonstrate highly variable responses, as seen in cancer patients.
This variability creates an opportunity to identify biomarkers associated with resistance or response to therapy by cross-matching PDX drug response profiles and molecular data (mutations, gene copy number, gene or protein expression data, miRNA data).
These cancer biomarkers can be used :
Our large PDX platform is dedicated to evaluate antitumor efficacy and to discover predictive biomarker in support of subsequent companion diagnostic development.
We have gathered one of the most diverse collection of highly characterized PDX models for solid tumors in various indications with a World leading collection for Breast cancers and pediatric models in-between others.
Cell lines derived from our PDX have also recently been made available for in vitro assays.
|Breast||TNBC, HER2+, ER+, PR+|
|Prostate||Primary hormone-dependent, Hormone-independent variant|
|Kidney||Renal Cell Carcinoma (RCC)|
|Skin||Melanoma, Merkel cell carcinoma|
|Pediatric liver tumors||Hepatoblastoma, Rhabdoid tumor|
Patient Derived Xenograft (PDX) Services : Maximum Tolerated Dose (MTD), Efficacy studies, Residual disease models,...
Xenograft Models Services. In addition to our in vivo direct PDX models, we also can run in vivo studies with any type of cell line injection.
Xentech has not received any reviews.
Xentech has not received any endorsements.